By Katherine Hamilton
Cytek Biosciences stock retreated Wednesday after the company said its preliminary fourth-quarter revenue was lower than expected and could be a decrease from 2023.
The Fremont, Calif.-based company, which specializes in cell analysis solutions, saw shares fall 13% to $6.34. The stock is down 20% over the past 12 months.
Cytek said it expects fourth-quarter revenue to be $57 million to $58 million, which would be a 2% decrease or flat compared with the same period of 2023. Analysts were expecting $61.5 million in quarterly revenue, per FactSet.
The company said its revenue for the full year 2024 should be $200 million to $201 million, based on preliminary data. That represents a 4% growth compared with the previous year. Analysts polled by FactSet were expecting $204.7 million in annual revenue.
The appreciation of the U.S. dollar negatively affected fourth-quarter revenue by about $1.5 million, Cytek said. There also were some order delays, Chief Executive Wenbin Jiang said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
January 15, 2025 10:11 ET (15:11 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。